PMID- 10641571
OWN - NLM
STAT- MEDLINE
DCOM- 20000204
LR  - 20071114
IS  - 1368-4736 (Print)
IS  - 1368-4736 (Linking)
VI  - 5
IP  - 3
DP  - 1999 Sep
TI  - Intradermal injection of granulocyte-macrophage colony-stimulating factor 
      (GM-CSF) in patients with metastatic melanoma recruits dendritic cells.
PG  - 139-44
AB  - Dendritic cells (DCs) are the main antigen-presenting cells in the skin. We 
      hypothesized that intradermal (i.d.) injection of granulocyte-macrophage 
      colony-stimulating factor (GM-CSF) would recruit DCs into melanoma skin 
      metastases and enhance autologous melanoma antigen presentation to host T cells. 
      Sixteen patients with cutaneous or subcutaneous melanoma metastases were treated 
      with GM-CSF injected i.d. into a single dermal metastasis and into a normal skin 
      site for 10 consecutive days at one of four dose levels (10, 20, 40, or 80 
      microg/injection). Pretreatment and post-treatment skin and tumor biopsies were 
      stained for a panel of T-cell, B-cell, macrophage, and DC immunohistochemical 
      markers. Positive cells were quantitated in a blinded fashion. There was a 
      significant increase in the number of DCs (HLA-DR+, S100+, factor XIIIa+) and 
      CD45R0+ T cells in the skin and in the tumors Injected with GM-CSF at all dose 
      levels. Uninjected control tumors showed no increase in HLA-DR+ cells or T-cell 
      infiltrate, but did show an Increase in S100+ and factor XIIIa+ cells, suggesting 
      a non-DC population. ID GM-CSF administered in this manner recruited DCs into 
      melanoma tumors and normal skin. Although no antitumor effects were seen, this 
      represents a potential method of preparing skin sites for vaccine delivery.
FAU - Nasi, M L
AU  - Nasi ML
AD  - Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 
      10021, USA.
FAU - Lieberman, P
AU  - Lieberman P
FAU - Busam, K J
AU  - Busam KJ
FAU - Prieto, V
AU  - Prieto V
FAU - Panageas, K S
AU  - Panageas KS
FAU - Lewis, J J
AU  - Lewis JJ
FAU - Houghton, A N
AU  - Houghton AN
FAU - Chapman, P B
AU  - Chapman PB
LA  - eng
GR  - P01 CA 33049/CA/NCI NIH HHS/United States
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - Cytokines Cell Mol Ther
JT  - Cytokines, cellular & molecular therapy
JID - 9713367
RN  - 0 (Antigens, Neoplasm)
RN  - 83869-56-1 (Granulocyte-Macrophage Colony-Stimulating Factor)
SB  - IM
MH  - Antigen Presentation/immunology
MH  - Antigens, Neoplasm/immunology
MH  - Dendritic Cells/*immunology
MH  - Granulocyte-Macrophage Colony-Stimulating Factor/*immunology/therapeutic use
MH  - Humans
MH  - Immunity, Cellular
MH  - Immunohistochemistry
MH  - Injections, Intradermal
MH  - Melanoma/drug therapy/*immunology/secondary
MH  - Skin Neoplasms/drug therapy/*immunology/secondary
EDAT- 2000/01/21 00:00
MHDA- 2000/01/21 00:01
CRDT- 2000/01/21 00:00
PHST- 2000/01/21 00:00 [pubmed]
PHST- 2000/01/21 00:01 [medline]
PHST- 2000/01/21 00:00 [entrez]
PST - ppublish
SO  - Cytokines Cell Mol Ther. 1999 Sep;5(3):139-44.